A practical reference on reversed-phase HPLC: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-03-23 and is reviewed periodically as new material appears.
Verification of research-grade material involves checking purity, sequence and counter-ion content against a certificate of analysis. Reported purity figures usually reflect chromatographic area percentage and do not by themselves establish biological activity. Independent laboratories may repeat mass confirmation and peptide mapping to detect substitutions or truncations. Open questions concern how residual solvents, trace metals and subtle conformational variants affect measured behavior, and how consistently different suppliers define their specifications. Documentation of analytical methods matters as much as the headline purity number when results are compared across studies.
Routine characterization relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry, to confirm identity and estimate purity. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates appended groups such as the fatty acid chain. Size-exclusion chromatography detects aggregates and fragments, while ion-exchange chromatography resolves charge variants. Circular dichroism and nuclear magnetic resonance supply secondary and higher-order structural information in research settings. No single technique covers every attribute, so laboratories combine orthogonal methods and compare outcomes against a reference standard where one exists.
Purified material is typically handled as a lyophilized powder kept at or below minus twenty degrees Celsius, shielded from light and moisture. In that state the solid remains stable for extended periods, although repeated freeze-thaw cycling can encourage aggregation. Once dissolved, aqueous solutions are less durable and are generally held cold and used within a brief window. Buffer composition, pH and ionic strength all influence degradation rates, and mildly acidic to neutral conditions are commonly examined. Actual shelf life depends on formulation, concentration and container, so stability limits are established experimentally rather than assumed.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Visual inspection serves only as a preliminary check |
| Solubility | Freely soluble in water and aqueous buffers | Gentle mixing may be needed to reach full dissolution |
| Typical storage | Minus 20 degrees Celsius or colder, desiccated, protected from light | Avoid repeated freeze-thaw cycles |
| Primary analytical method | Reversed-phase HPLC with mass detection | Purity reported as chromatographic area percent |
| Common synonyms | GIP/GLP-1 dual agonist; LY3298176 | Development codes are distinct from approved product names |
在生理层面，GIP 与 GLP-1 均为肠道内分泌细胞分泌的肠促胰素，进食后参与胰岛素分泌调节与胃排空抑制。Tirzepatide 通过同时激活这两条信号通路，使胰岛素分泌的葡萄糖依赖性增强，并延缓冲胃排空、降低食欲信号。与单一 GLP-1 激动相比，双靶点作用在血糖控制和体重变化上的效应幅度更大，但具体贡献比例仍在研究之中。
脂肪酸侧链的存在使该肽与血浆白蛋白结合能力增强，从而延长循环半衰期，支持每周一次给药的用药间隔。白蛋白结合同时改变组织分布特征，减慢肾脏清除速度。该设计思路在多种长效肽类药物中被反复采用，属于既定的药代动力学策略。
The peptide shares degradation routes common to modified peptides: deamidation of asparagine and glutamine residues, oxidation of methionine, and backbone hydrolysis under extreme pH. Lyophilized material is generally more stable than a solution, and residual water content directly affects the rate of hydrolysis. In liquid form, aggregation and visible particles can appear after agitation or repeated freeze-thaw cycles. Stability studies therefore track monomer content, aggregate content, and potency over months under defined temperature and humidity.
Cold-chain handling is standard for formulated product, with dry powder stored frozen and ready-to-use solutions refrigerated. Light exposure is minimized because photodegradation of certain amino acid side chains is possible. Shipping and temperature-excursion studies are used to establish whether short deviations affect quality attributes. Documentation supplied with research material usually includes a certificate of analysis listing purity, identity confirmation, and water or residual solvent content. Users are expected to confirm that material meets the stated specification before use.
Identity and purity of tirzepatide are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Because the molecule carries several modifications, gradient conditions are adjusted to resolve the intact peptide from deamidation and oxidation products. Enzymatic digestion followed by peptide mapping confirms the primary sequence and locates specific modifications. Quantitation in biological matrices typically uses liquid chromatography with tandem mass spectrometry after solid-phase extraction. Immunoassays are used less often, since antibody cross-reactivity with closely related peptides can bias results.
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
Common degradation routes include hydrolysis of labile amide bonds, deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation. Aggregates can form during freeze-thaw cycling, at elevated pH, or when peptide concentration is high. Each route produces characteristic chromatographic or mass shifts that are tracked during stability studies. Whether a given minor impurity alters biological activity is often an open question, and specification limits are typically set on identity and purity rather than on functional data for trace species.
Lyophilized material is generally held at -20 degrees Celsius or lower, desiccated and protected from light, where it remains stable for extended periods. Reconstituted or ready-to-use solution is usually kept at 2 to 8 degrees Celsius with minimal agitation. Repeated freeze-thaw cycles should be avoided because they promote aggregation and reduce the soluble monomer fraction. Shipment of frozen solid commonly uses dry ice, while refrigerated liquid moves with validated cold packs. Stability beyond documented periods is not established.
Retrolental tract: Extends posteriorly from the hyaloideocapsular ligament into central vitreous Coronary tract: External to the retrolental tract, and excluding posteriorly from a circular zone overlying the posterior 1/3rd of the ciliary processes Median tract: Extends back from a circular zone external to the coronary tract, at the anterior margin of the vitreous base Preretinal tract: Extends back from the ora serrata and vitreous base
== Distribution and habitat == Species in the family Conidae are found in the tropical and subtropical seas of the world, in four biogeographic regions, including: the Indo-Pacific (with 60% of all species), the Tropical Eastern Pacific, the western Tropical Atlantic, and the eastern Tropical Atlantic, plus 10 species in the warm temperate Agulhas bioregion on the southern coast of South Africa. Fewer than one percent of fossil species have been found in more than one of the above regions. Cone snails are typically found in warm tropical seas and oceans worldwide. Cone snails reach their greatest diversity in the Western Indo-Pacific region. While the majority of cone snails are found in warm tropical waters, some species have adapted to temperate/semi-tropical environments and are endemic to areas such as the Cape coast of South Africa, the Mediterranean, or the cool subtropical waters of southern California (Californiconus californicus). They live on a variety of substrates, from the intertidal zone and deeper areas, to sand, rocks or coral reefs.
Infliximab, a chimeric monoclonal antibody, sold under the brand name Remicade among others, is a medication used to treat a number of autoimmune diseases. This includes Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, and Behçet's disease. It is given by slow injection into a vein, typically at six- to eight-week intervals. Common side effects include infections, acute infusion reactions, and abdominal pain. Infliximab is a chimeric monoclonal antibody biologic. It seems to work by binding to and neutralizing TNF, preventing it from interacting with its receptors on the cell. TNF is a chemical messenger (cytokine) and a key part of the autoimmune reaction. Infliximab was originally developed in mice as a mouse antibody. Because humans have immune reactions to mouse proteins, the mouse common domains were replaced with similar human antibody domains. They are monoclonal antibodies and have identical structures and affinities to the target. Because they are a combination of mouse and human antibody amino acid sequences, they are called a "chimeric monoclonal antibody". Infliximab was approved for medical use in the United States in 1998, and in the European Union in August 1999. Infliximab biosimilars have been approved in the EU (2013), in Japan (2014), and in the United States (2016, 2017, 2019). Infliximab is a therapeutic alternative on the World Health Organization's List of Essential Medicines.
=== Morphological data === The fact that substitution models can be used to analyze any biological alphabet has made it possible to develop models of evolution for phenotypic datasets (e.g., morphological and behavioural traits). Typically, "0" is. used to indicate the absence of a trait and "1" is used to indicate the presence of a trait, although it is also possible to score characters using multiple states. Using this framework, we might encode a set of phenotypes as binary strings (this could be generalized to k-state strings for characters with more than two states) before analyses using an appropriate mode. This can be illustrated using a "toy" example: we can use a binary alphabet to score the following phenotypic traits "has feathers", "lays eggs", "has fur", "is warm-blooded", and "capable of powered flight". In this toy example hummingbirds would have sequence 11011 (most other birds would have the same string), ostriches would have the sequence 11010, cattle (and most other land mammals) would have 00110, and bats would have 00111. The likelihood of a phylogenetic tree can then be calculated using those binary sequences and an appropriate substitution model. The existence of these morphological models make it possible to analyze data matrices with fossil taxa, either using the morphological data alone or a combination of morphological and molecular data (with the latter scored as missing data for the fossil taxa).
Sources: en.wikipedia.org
The Essendon Football Club, nicknamed the Bombers or colloquially the Dons, is a professional Australian rules football club that plays in the Australian Football League (AFL), the game's premier competition. Formed by the McCracken family in their Ascot Vale home in 1872, the club played its first recorded game in 1873. From 1878 until 1896, the club played in the Victorian Football Association (VFA), where it won four consecutive premierships between 1891 and 1894. In 1896, Essendon joined seven other clubs to form the breakaway Victorian Football League (known as the AFL since 1990), winning the inaugural VFL premiership in 1897. Headquartered at Windy Hill from 1922 to 2013, the club moved to The Hangar in late 2013. The club currently shares its home games between Docklands Stadium and the Melbourne Cricket Ground. Andrew McGrath serves as the club captain as of 2026. Essendon is one of Australia's most successful and prominent football clubs, having won 16 VFL/AFL premierships, which is tied (along with Carlton and Collingwood) for the most of any club in the competition. The club experienced notable golden eras under captain-coach Dick Reynolds in the 1940s and 1950s, and under coach Kevin Sheedy from the 1980s to the early 2000s, cultivating the iconic "Baby Bombers" team in 1993 and recording a historically dominant season in 2000. However, the club has struggled to achieve significant on-field success in the 21st century, having not won a finals match since 2004.
=== Books === 1910 Conflicts in the Child's Soul 1912 Psychology of the Unconscious 1916 Seven Sermons to the Dead (a part of the Red Book, published privately) 1921 Psychological Types 1933 Modern Man in Search of a Soul (essays) 1944 Psychology and Alchemy 1951 Aion: Researches into the Phenomenology of the Self 1952 Symbols of Transformation (revised edition of Psychology of the Unconscious) 1954 Answer to Job 1956 Mysterium Coniunctionis: An Inquiry into the Separation and Synthesis of Psychic Opposites in Alchemy 1957 The Undiscovered Self 1959 Flying Saucers: A Modern Myth of Things Seen in the Skies (Translated by R. F. C. Hull) 1960 Synchronicity: An Acausal Connecting Principle 1962 Memories, Dreams, Reflections (autobiography, co-written with Aniela Jaffé) 1964 Man and His Symbols (Jung contributed one part, his last writing before his death in 1961; the other four parts are by Marie-Louise von Franz, Joseph L. Henderson, Jaffé, and Jolande Jacobi) 2009 The Red Book: Liber Novus (manuscript produced c. 1915–1932) 2020 Black Books (private journals produced c. 1913–1932, on which the Red Book is based)
Active packaging refers to packaging systems designed to perform functions beyond passive containment and physical protection. Active materials deliberately absorb or release substances in order to extend shelf life or maintain or improve the condition of a packaged product. Intelligent packaging monitors the condition of the product, the atmosphere inside the package, or conditions encountered during storage and distribution. The terms active packaging, intelligent packaging, and smart packaging are related and can overlap. Smart packaging is commonly used as a broader term for systems that detect, record, communicate, or respond to changes affecting a packaged product. Active and intelligent systems are used with food, pharmaceuticals, medical products, electronics, industrial components, agricultural products, and other goods that are sensitive to oxygen, moisture, microorganisms, temperature, light, physical damage, or tampering.
Sources: en.wikipedia.org
Liquid chromatography combined with mass spectrometry is the most common approach. Digestion followed by peptide mapping verifies the sequence and modification sites. Results are judged against a reference standard or a theoretically calculated mass.
Lower temperatures slow most degradation routes, and storage at minus twenty degrees Celsius or below is standard for lyophilized material. Repeated warming and cooling imposes stress on the molecule. Dissolved samples deteriorate faster and are usually handled over shorter periods.
It normally reflects the relative chromatographic area of the principal peak. It does not capture every possible impurity or demonstrate biological function. Additional methods are required to describe a sample completely.
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.